Brion W. Murray joined Turning Point Therapeutics in June of 2019 as the Vice President of Cancer Biology. Brion and his team are responsible for identifying new therapeutic opportunities and supporting the discovery of innovative molecules that address unmet medical needs.
He received a B.S in Chemistry from the University of North Carolina at Chapel Hill; a Ph.D. in Biochemistry from the University of Maryland; and post-doctoral training at The Scripps Research Institute. He has 23 years of prior drug discovery and cancer biology experience at Celgene and Pfizer. Brion’s career focuses on understanding cancer biology on a molecular level and creating effective therapies. At Pfizer Oncology, he contributed to the discovery and/or development of six FDA-approved drugs (Inlyta, Xalkori, Ibrance, Bosulif, Vizimpro, Sutent) and many investigational drugs. He is the sole inventor for the use of Inlyta in drug-resistant leukemia. Brion has made fundamental scientific discoveries in the fields of biochemistry, cellular signaling, and cancer biology which have resulted in 70 top-tier publications and 13 patents. He serves as a senior editor for American Association of Cancer Research journal Molecular Cancer Therapeutics and is a member of the Faculty of 1000 (2018 Member of the Year for chemical biology). In addition, Brion is the spouse of a breast cancer survivor and continues to help cancer patients understand their disease and therapeutic options.